The Minneapolis life-sciences supplier turned a catalog of repeat-purchase reagents into a $1.2 billion business. Its best lesson is not the pending $11.3 billion exit - it is how one expensive diagnostics detour forced the portfolio back toward tools that scale.
Life Technologies vanished as an independent company in 2014. Its brands did not - they became the quiet infrastructure behind experiments in genomics, cell biology, medicine and forensics.